Possibilities of adjusting low calcitriol levels in patients on dialysis;Možnosti úpravy nízkých hladin kalcitriolu u dialyzovaných pacientů

Osteologicky Bulletin

Volumn 7, Issue 1, 2002, Pages 26-29

  Sulkova S ^a   Schestauberova E ^a   Svara F ^a   Fortova M ^a   Uhrova J ^a   Zima, T ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Calcitriol; Renal failure; Renal osteopathy

Indexed keywords

ALFACALCIDOL; ALKALINE PHOSPHATASE; CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL; CALCIUM; DIALYSIS FLUID; PARATHYROID HORMONE; PHOSPHATE;

ADULT; AGED; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; PHOSPHATE BLOOD LEVEL; RENAL OSTEODYSTROPHY; REVIEW; VITAMIN BLOOD LEVEL; VITAMIN DEFICIENCY;

EID: 0036298291     PISSN: 12113778     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. A deficit of calcitriol may not be the initial factor in the pathogenesis of secondary hyperparathyreoidism
2. Pathogenesis of secondary hyperparathyreoidism
3. Phosphorus, regulation of plasma calcium, and secondary hyperparathyreoidism: A hypothesis to integrate a historical and modern perspective
4. Mechanism of vitamin D action and its regulation
5. Vliv 1,25-dihydroxycholekalciferolu na imunitní a klinický stav a na parametry fosfokalciového metabolismu dialyzovaných pacíentů
6. Are recent findings on 1,25-dihydroxycholecalciferol metabolism relevant for the pathogenesis of uremia
7. What's new in vitamin D for the nephrologist
8. Vitamin D deficiency is implicated in reduced serum albumin concentration in patients with end-stage renal disease
9. Osteodystrophy in the millenium
10. Management of the renal patient: Experts' recommendations and clinical algorithms on renal osteodystrophy and cardiovascular risk factors
11. Fournier 1-alpha-hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: Justification and optimal modalities of administration
12. Low-dose calcitriol prevents the rise in 1,84 iPTH without affecting serum calcium and phsphate in atients with morerate renal failure (prospective placebo-controlled multicentre trial)
13. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure
14. Parametry kostního metabolismu u pacientů s chronickým selháním ledvin, diplomová práce
15. Kinetics of serum 1,84iPTH after high dose of calcitriol in uremic patients
16. Optimum route of administration of vitamin D in renal failure
17. Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-dihydroxyvitamin D in nondialyzed patients with chronic renal failure
18. Free and total 1,25-dihydroxyvitamin D levels in subjects with renal disease
19. 3 in Japan
20. Can the fast bone loss in osteoporotic and osteopenic patients be stopped with active vitamin D metabolites
21. Mouse primary osteoblasts express vitamin D3 25-hydroxylase mRNA and convert 1 alpha-hydroxyvitamin D3 into 1 alpha, 25-dihydroxyvitamin D3
22. Bioavailability of calcitriol after oral, intravenous and intraperitoneal doses in dialysis patients
23. The actions and therapeutic applications of 1α-hydroxylated derivatives of vitamin D